Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Esophageal Neoplasms 1Deglutition Disorders 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 213Irinotecan 146Leucovorin 140Gemcitabine 124S 1 (combination) 110apatinib 109Cisplatin 102Bevacizumab 99Drug Therapy 98Radiotherapy 97Paclitaxel 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 53toripalimab 52Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × epigallocatechin gallate × Gastrointestinal × Clear all
NCT06398405 2024-05-03

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

Shandong Cancer Hospital and Institute

Phase 2 Unknown
72 enrolled
Gastrointestinal

Deglutition Disorders, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡